Paxmedica, Inc. (NASDAQ: PXMD) was founded in 2018 and is headquartered in Woodcliff Lake, New Jersey, USA, with 4 full-time employees. It is an early clinical stage biopharmaceutical company dedicated to the development of anti-purine therapy (APT) to treat neurodevelopmental disorders , Including autism spectrum disorder (Autism Spectrum Disorder, ASD) and Fragile X syndrome tremor ataxia (FXTAS).
Paxmedica, Inc. (PXMD):
PaxMedica is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for the unmet needs of neurodevelopmental disorders. The company’s main plan focuses on two of the most challenging conditions in the world-Autism Spectrum Disorder (ASD) and Fragile X Syndrome Tremor Ataxia (FXTAS).
Currently, there is no FDA approved treatment for the core symptoms of ASD, and there is no FDA approved treatment for FXTAS. PaxMedica was born to change this situation.
Paxmedica, Inc. (PXMD) investment:
Paxmedica, Inc. (NASDAQ: PXMD) plans to issue a price of $5.50-$6.50, issue 2.5 million shares, raise 15 million US dollars, underwriting by The Benchmark Company/ Brookline Capital Markets (a division of Arcadia Securities), and the listing date is to be determined.